{"entity":{"id":"paper-nct05009329-nat-med-2025","kind":"paper","name":"Glecirasib in KRAS G12C -mutated nonsmall-cell lung cancer: a phase 2b trial","aka":[],"tldr":"Published report from the trial registered as NCT05009329, in Nature Medicine (2025), chosen as the most cited paper whose own text cites the registry id.","summary":"Glecirasib (JAB-21822) is a new covalent oral KRAS-G12C inhibitor. This multicenter, single-arm phase 2b study assessed the efficacy and safety of glecirasib administered orally at 800 mg daily in patients with locally advanced or metastatic KRAS G12C -mutated nonsmall-cell lung cancer. The primary endpoint was the objective response rate (ORR) assessed by an independent review committee (IRC). Between 15 September 2022 and 28 September 2023, 119 patients with a median age of 62 years were enrolled. at the data cut-off date on 28 March 2024, the ORR assessed by IRC was 47.9% (56/117; 95% confidence interval: 38.5-57.3%). The incidence of treatment-related adverse events (TRAEs) of any grade was 97.5% (116/119). The incidence of grades 3 and 4 TRAEs was 38.7% (46/119). A total of 5.0% (6/119) of patients discontinued the treatment due to TRAEs. No treatment-related deaths occurred. Glecirasib exhibited promising clinical efficacy and manageable safety profiles in these patient populations. ClinicalTrials.gov identifier: NCT05009329.\n\nIndexed on Europe PMC as PubMed record 39762419 (DOI 10.1038/s41591-024-03401-z). Its abstract cites the registry id NCT05009329, which is how it was matched to this trial; no figure has been checked by an editor.","asOf":"2026-09-22","links":[{"label":"Nat Med 2025","url":"https://doi.org/10.1038/s41591-024-03401-z"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/39762419/"},{"label":"Europe PMC","url":"https://europepmc.org/article/MED/39762419"},{"label":"ClinicalTrials.gov NCT05009329","url":"https://clinicaltrials.gov/study/NCT05009329"}],"tags":["europepmc-ingest"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct05009329"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["nature-medicine"],"dependsOn":[],"notes":[],"journal":"Nature Medicine","year":2025,"doi":"10.1038/s41591-024-03401-z","pmid":"39762419","authors":"Shi Y, Fang J, Xing L, et al.","paperType":"observational","findings":[],"whatItMeans":"This is the paper Europe PMC returns for registry id NCT05009329 with the most citations, so it is the natural first reading for anyone following the trial. Read the abstract above alongside the trial page and the registry entry; the record was linked automatically and its figures have not been checked by hand.","caveats":["Matched to the trial by the registry id cited in the Europe PMC record; the summary reproduces the record's abstract and no figure has been verified against the full paper."]},"route":"/key-papers/paper-nct05009329-nat-med-2025/","neighbours":{"trial":[{"id":"nct05009329","kind":"trial","name":"A Study of JAB-21822 in Adult Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation in China","route":"/trials/nct05009329/"}],"journal":[{"id":"nature-medicine","kind":"journal","name":"Nature Medicine","route":"/journals/nature-medicine/"}]}}